心肌保护
医学
周细胞
效应器
内科学
心脏病学
缺血
缺血预处理
心肌缺血
血管平滑肌
心肌梗塞
动脉发生
心力衰竭
骨骼肌
药理学
动脉
冠状动脉
细胞生物学
再灌注损伤
急性冠脉综合征
心肌细胞
小动脉
冠状动脉循环
化学
作者
Svetlana Mastitskaya,Felipe Freitas,Lowri Evans,David Attwell
标识
DOI:10.1038/s41467-026-69555-1
摘要
Abstract Failure to reperfuse the coronary microvasculature (“no-reflow”) affects up to 50% of patients after unblocking a coronary artery that was causing ischaemia and acute myocardial infarction. This “no-reflow” is associated with reduced left ventricular ejection fraction, increased infarct size and death. We show that the incretin hormone GLP-1 (glucagon-like peptide 1) can be used to protect the heart after ischaemia by activating ATP-sensitive K + channels on pericytes that constrict coronary capillaries. Coronary capillary dilation can be activated pharmacologically or by vagally-mediated GLP-1 release from the gut evoked by skeletal muscle ischaemia, and is abolished by block or genetic deletion of pericyte K ATP channels. These results define a brain-gut-heart pathway mediating cardioprotection and suggest pharmacological therapies to reduce ischaemia-induced coronary no-reflow and improve post-infarct recovery.
科研通智能强力驱动
Strongly Powered by AbleSci AI